Caladrius Biosciences Inc (CLBS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Caladrius Biosciences Inc (CLBS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3481
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Caladrius Biosciences Inc (Caladrius), formerly NeoStem Inc, is a cell therapy service provider. The company offers multiple technology platforms targeting cardiovascular indications and autoimmune diseases. It offers products to target type one diabetes mellitus, used to treat imbalance in an immune system, to treat condition caused by ischemia, and to repair and regenerate cardiovascular tissue. Caladrius provide technology that helps cells by enabling the body to rebalance irregularities. The company offers T regulatory technology and CD34 technology. It offers services such as product and process development, engineering and automation, GMP manufacturing, cell and tissue processing, storage and distribution, and expert consulting and regulatory support. Caladrius serves biotechnology, pharmaceutical and medical product companies, and academic research institutions. The company operates in Basking Ridge, Irvine and New York, the US. Caladrius is headquartered in Basking Ridge, New Jersey, the US.

Caladrius Biosciences Inc (CLBS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
Kiadis Pharma Enters into Agreement with PCT 15
Caladrius Biosciences Enters into Development Agreement with Sanford Research 16
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 17
NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 18
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 19
Licensing Agreements 21
Caladrius Biosciences Enters into Licensing Agreement with Shire 21
Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 22
Hitachi Chemical Enters into Licensing Agreement with Progenitor Cell Therapy 23
AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 24
SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 25
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 29
Equity Offering 30
Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 30
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 31
Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 33
Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 35
Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 37
Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 38
NeoStem Raises USD29 Million in Public Offering of Shares 39
NeoStem to Raise USD30 Million in Private Placement of Shares 40
NeoStem Completes Public Offering Of Shares For US$40.25 Million 41
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 42
NeoStem Completes Public Offering Of Shares For US$11.5 Million 43
NeoStem Completes Private Placement Of Common Stock For US$3 Million 44
NeoStem Completes Public Offering Of Units For US$6.8 Million 46
Acquisition 48
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 48
Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 50
NeoStem Completes Acquisition Of California Stem Cell 51
NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For US$12 Million 53
Caladrius Biosciences Inc – Key Competitors 54
Caladrius Biosciences Inc – Key Employees 55
Caladrius Biosciences Inc – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
Financial Announcements 57
Aug 09, 2018: Caladrius Biosciences reports 2018 second quarter and first six months financial results 57
May 10, 2018: Caladrius Biosciences Reports 2018 First Quarter Financial Results 59
Mar 22, 2018: Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results 60
Nov 09, 2017: Caladrius Biosciences Reports 2017 Third Quarter Results 62
Aug 10, 2017: Caladrius Biosciences Reports 2017 Second Quarter Results 64
May 15, 2017: Caladrius Biosciences Announces 2017 First Quarter Financial Results 66
Mar 17, 2017: Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results 68
Other Significant Developments 70
Jul 02, 2018: Dr. Marilyn Glassberg Presents Findings on Stem Cell Treatments for Lung Diseases 70
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Kiadis Pharma Enters into Agreement with PCT 15
Caladrius Biosciences Enters into Development Agreement with Sanford Research 16
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 17
NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 18
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 19
Caladrius Biosciences Enters into Licensing Agreement with Shire 21
Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 22
Hitachi Chemical Enters into Licensing Agreement with Progenitor Cell Therapy 23
AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 24
SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 25
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 29
Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 30
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 31
Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 33
Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 35
Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 37
Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 38
NeoStem Raises USD29 Million in Public Offering of Shares 39
NeoStem to Raise USD30 Million in Private Placement of Shares 40
NeoStem Completes Public Offering Of Shares For US$40.25 Million 41
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 42
NeoStem Completes Public Offering Of Shares For US$11.5 Million 43
NeoStem Completes Private Placement Of Common Stock For US$3 Million 44
NeoStem Completes Public Offering Of Units For US$6.8 Million 46
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 48
Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 50
NeoStem Completes Acquisition Of California Stem Cell 51
NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For US$12 Million 53
Caladrius Biosciences Inc, Key Competitors 54
Caladrius Biosciences Inc, Key Employees 55
Caladrius Biosciences Inc, Other Locations 56
Caladrius Biosciences Inc, Subsidiaries 56

List of Figures
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Caladrius Biosciences Inc (CLBS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Centers for Disease Control and Prevention-製薬・医療分野:企業M&A・提携分析
    Summary Centers for Disease Control and Prevention (CDC), a subsidiary of US Department of Health and Human Services is a public health institute that offers health, safety and security threat management solutions. The institute provides health information to fight diseases and support communities f …
  • Baoding Lightway Green Energy Technology Co Ltd:企業の戦略的SWOT分析
    Baoding Lightway Green Energy Technology Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • British American Tobacco (Malaysia) Berhad:戦略・SWOT・企業財務分析
    British American Tobacco (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report Summary British American Tobacco (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Ivy Cosmetics Corporation:企業の戦略・SWOT・財務情報
    Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report Summary Ivy Cosmetics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • FirstGroup plc (FGP):企業の財務・戦略的SWOT分析
    FirstGroup plc (FGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Fugro NV (FUR):企業の財務・戦略的SWOT分析
    Fugro NV (FUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Ypsomed Holding AG (YPSN)-医療機器分野:企業M&A・提携分析
    Summary Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops and manufactures injection systems. Its offers pen injectors, autoinjectors, dual chamber pens and other custom products. The company also offers contract manufacturing, industrial design, human factors engineerin …
  • Mount Tam Biotechnologies Inc (MNTM):企業の財務・戦略的SWOT分析
    Summary Mount Tam Biotechnologies Inc (Mount Tam Biotechnologies), a subsidiary of TabacaleraYsidron Inc is a provider of pharmaceutical products that offers development and commercialization of medical compounds for autoimmune diseases. The company’s lead product candidate TAM-0, a rapamycin analog …
  • Benihana Inc.:企業の戦略・SWOT・財務情報
    Benihana Inc. - Strategy, SWOT and Corporate Finance Report Summary Benihana Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • EDP – Energias de Portugal, SA:戦略・SWOT・企業財務分析
    EDP - Energias de Portugal, SA - Strategy, SWOT and Corporate Finance Report Summary EDP - Energias de Portugal, SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • TiGenix NV (TIG):医療機器:M&Aディール及び事業提携情報
    Summary TiGenix NV (TiGenix), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that develops and commercializes novel therapeutic products. The company exploits the anti-inflammatory properties of stem cells to develop novel therapies. It offers products such as AlloCSC-0 …
  • Kobayashi Pharmaceutical Co Ltd (4967)-医療機器分野:企業M&A・提携分析
    Summary Kobayashi Pharmaceutical Co Ltd (Kobayashi) is a manufacturer and distributor of pharmaceutical, health and personal care products. The company offers OTC pharmaceuticals, oral hygiene products, deodorizing air fresheners, cooling gel sheets, sanitary products, household sundries, and body w …
  • DFDS AS (DFDS):企業の財務・戦略的SWOT分析
    DFDS AS (DFDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • EnBW Energie Baden-Wurttemberg AG (EBK):企業の財務・戦略的SWOT分析
    EnBW Energie Baden-Wurttemberg AG (EBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Merck KGaA:企業のM&A・事業提携・投資動向
    Merck KGaA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merck KGaA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Windflow Technology Ltd (WTL):企業の財務・戦略的SWOT分析
    Windflow Technology Ltd (WTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Elementis plc (ELM):企業の財務・戦略的SWOT分析
    Elementis plc (ELM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Nymox Pharmaceutical Corp (NYMX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nymox Pharmaceutical Corp (Nymox) is a biopharmaceutical company that undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company markets diagnostic products for measuring tobacco product exposure and for the …
  • Canadian Tire Corp Ltd (CTC.A):企業の財務・戦略的SWOT分析
    Canadian Tire Corp Ltd (CTC.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Southern Co (SO):企業の財務・戦略的SWOT分析
    Southern Co (SO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆